|Gregory F. Heath, Ph.D.|
Senior Vice President & General Manager, Diagnostics
Greg Heath is responsible for managing Illumina’s emerging diagnostics business, specifically overseeing the development of diagnostic content for the BeadXpress system, and ultimately for the Illumina’s sequencing platform.
Greg has more than 20 years of experience in the diagnostics field, including launching the first FDA-approved microarray for diagnostic use. Greg joined Illumina from Roche Molecular Systems where he held a number of senior executive positions including head of clinical genomics, senior vice president of global product marketing, senior vice president of global marketing and business development, and most recently, senior vice president of global business. In this last role, Greg was responsible for new product development and global marketing activities for the infectious disease, blood screening, genetics and oncology portfolios. Greg was also responsible for the PCR licensing, industrial business, and business development programs. From 2000–2003, Greg was head of business development and licensing for the diagnostics division of F. Hoffman La Roche in Basel and led the strategic planning, business development, and licensing activities of the molecular diagnostics, centralized diagnostics, applied science, near patient testing, and diabetes care business areas. Prior to this, Greg held numerous roles in marketing and business development with Roche Diagnostics’ U.S. affiliate.
Greg graduated with a B.S. in psychology from Illinois State University and an M.A. in experimental psychology from Hollins College. He earned a Ph.D. in experimental psychology from Virginia Commonwealth University and completed his post-doctoral work in behavioral pharmacology at Michigan State University. Outside of his work at Illumina, Greg has also published more than 25 articles in science and business and participates in various internal and external leadership programs.